<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ABACAVIR SULFATE- abacavir sulfate tablet, film coated </strong><br>Apotex Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use ABACAVIR TABLETS, USP safely and effectively. See full prescribing information for ABACAVIR TABLETS, USP.</span><br><br><span class="Bold">ABACAVIR <span class="Bold">tablets</span>, for oral use <br>Initial U.S. Approval: 1998 </span>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span></span></span></h1>
<h1 class="Warning"><span class="Italics"><span class="Bold">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with abacavir (abacavir sulfate). (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome. (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold">Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold">Discontinue abacavir as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected. Regardless of HLA-B*5701 status, permanently discontinue abacavir if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible. (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, NEVER restart abacavir tablets or any other abacavir-containing product. (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. (<a href="#i4i_section_id_c829b3a3-8657-4da8-aebe-5df2726c86e9">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, Use with Other Abacavir-containing Products (<a href="#_d2301bbf-db0f-0bc1-247d-84f3d79eca66">5.6</a>) 03/2015 </p></div>
</div>
<div><div></div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span></span></span></h1>
<h1 class="Warning"><span class="Italics"><span class="Bold">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with abacavir (abacavir sulfate). (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome. (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold">Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold">Discontinue abacavir as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected. Regardless of HLA-B*5701 status, permanently discontinue abacavir if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible. (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, NEVER restart abacavir tablets or any other abacavir-containing product. (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. (<a href="#i4i_section_id_c829b3a3-8657-4da8-aebe-5df2726c86e9">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Abacavir, a nucleoside analogue, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. (<a href="#i4i_indications_id_915317a8-7410-45b2-9f99-100765b3277c">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>A medication guide and warning card should be dispensed with each new prescription and refill. (<a href="#i4i_dosage_admin_id_cb3836e8-feaa-4988-a12f-87771660c975">2</a>) </li>
<li>Adults: 600 mg daily, administered as either 300 mg twice daily or 600 mg once daily. (<a href="#i4i_section_id_946b8c2e-aa5b-438c-97b9-af05d87a3c42">2.1</a>) </li>
<li>Pediatric Patients Aged 3 Months and Older: Administered twice daily. Dose should be calculated on body weight (kg) and should not exceed 600 mg daily. (<a href="#_175da327-6944-8672-16e7-876cccb9d5e6">2.2</a>) </li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> – 200 mg twice daily; moderate/severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> – contraindicated. (<a href="#i4i_section_id_77feaa4f-f24b-4167-811e-fbbc5af95896">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta"> </p>
<ul><li>Tablets: 300 mg, functionally scored (<a href="#i4i_dosage_form_strength_id_626eab63-cbf9-49a0-aebe-998ecd111cb9">3</a>)</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir. (<a href="#i4i_contraindications_id_45f72e52-431e-430b-90f1-5daf10bd17fb">4</a>, <a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</li>
<li>Moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (<a href="#i4i_contraindications_id_45f72e52-431e-430b-90f1-5daf10bd17fb">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>: Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with abacavir tablets and other abacavir-containing products. Read full prescribing information section 5.1 before prescribing abacavir tablets. (<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis have been reported with the use of nucleoside analogues. (<a href="#i4i_section_id_c829b3a3-8657-4da8-aebe-5df2726c86e9">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> (<a href="#i4i_section_id_d0856894-9c54-42f6-b3a1-684c51768788">5.3</a>) and redistribution/accumulation of body fat have been reported in patients treated with combination antiretroviral therapy. (<a href="#i4i_section_id_917c3387-e958-44f6-ad3c-60cf15a55fb1">5.4</a>)</li>
<li>Administration of abacavir with other products containing abacavir is not recommended. (<a href="#_d2301bbf-db0f-0bc1-247d-84f3d79eca66">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>The most commonly reported adverse reactions of at least moderate intensity (incidence greater than or equal to 10%) in adult HIV-1 clinical trials were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and dreams/<span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span>. (<a href="#i4i_section_id_b06f9bb5-9498-44f1-9c76-052b312d30a5">6.1</a>) </li>
<li>The most commonly reported adverse reactions of at least moderate intensity (incidence greater than or equal to 5%) in pediatric HIV-1 clinical trials were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, and ear/nose/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span>. (<a href="#_e200f77d-ae4d-c058-c604-4e65f3a175d3">6.2</a>) <p class="Highlighta"><span class="Bold"></span> </p>
</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp., at 1-800-706-5575 or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics Underline">www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Ethanol: Decreases elimination of abacavir. (<a href="#_f6174652-918f-ea16-5502-a8909f6a7c6f">7.1</a>)</li>
<li>Methadone: An increased methadone dose may be required in a small number of patients. (<a href="#_0bcc72e2-f624-baad-24b3-fd70a3d4f886">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta">Lactation: Breastfeeding not recommended. (<a href="#i4i_nursing_mothers_id_34b1f397-75cf-48d4-9b03-a92c3fce4ac3">8.2</a>) </p>
<p class="Highlighta"><span class="Bold"><br><br>Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Company’s ZIAGEN<span class="Sup">®</span> (abacavir sulfate) tablets and oral solution. However, due to ViiV Healthcare Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span></a></h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Fat Redistribution</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Use with Other Abacavir-containing Products</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience in Adult Subjects</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 <span class="None"> Clinical Trials Experience in Pediatric Subjects</span></a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">
         7.1 Ethanol
      
   </a></h2>
<h2><a href="#section-7.2" class="toc">
      7.2 Methadone
   </a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc"><span class="None">8.1 Pregnancy </span></a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Lactation</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adult Trials</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Pediatric Trials</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES </a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Warning">
<a name="_0d4d275e-4b1b-4d08-3a5e-3b8a6d340f2e"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>, AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span></h1>
<p class="First"><span class="Bold"></span><span class="Bold"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </span><span class="Bold"></span><span class="Bold"><br>Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with abacavir (abacavir sulfate).</span></span><span class="Bold">    </span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in two or more of the following groups: (1) <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, (2) <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, (3) gastrointestinal (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>), (4) constitutional (including generalized <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or achiness), and (5) respiratory (including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>). Discontinue abacavir as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected.</span><span class="Bold">       </span></p>
<p><span class="Bold">Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative patients may develop a suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</span><span class="Bold">        </span></p>
<p><span class="Bold">Regardless of HLA-B*5701 status, permanently discontinue abacavir if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible.</span></p>
<p><span class="Bold"></span><span class="Bold">Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, NEVER restart abacavir tablets or any other abacavir-containing product because more severe symptoms can occur within hours and may include <span class="Bold">life-threatening</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span><span class="Bold">         </span></p>
<p><span class="Bold">Reintroduction of abacavir tablets or any other abacavir-containing product, even in patients who have no identified history or unrecognized symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir therapy, can result in serious or fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Such reactions can occur within hours </span><span class="Bold Italics">[see <a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">Warnings and Precautions (5.1)</a>]</span><span class="Bold">.</span></p>
<p><span class="Bold"></span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> <br><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir and other antiretrovirals </span><span class="Bold Italics">[see <a href="#i4i_section_id_c829b3a3-8657-4da8-aebe-5df2726c86e9">Warnings and Precautions (5.2)</a>]</span><span class="Bold">.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_915317a8-7410-45b2-9f99-100765b3277c"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<p>Additional important information on the use of abacavir tablets for treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>: </p>
<p>Abacavir tablets are one of multiple products containing abacavir. Before starting abacavir tablets, review medical history for prior exposure to any abacavir-containing product (including EPZICOM<span class="Sup">®</span>, TRIUMEQ<span class="Sup">®</span>, and TRIZIVIR<span class="Sup">®</span>) in order to avoid reintroduction in a patient with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir <span class="Italics">[<a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">see Warnings and Precautions (5.1), </a><a href="#i4i_adverse_effects_id_b03c877b-7741-46cb-a5c1-467beeac906a">Adverse Reactions (6)]</a>.</span></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_cb3836e8-feaa-4988-a12f-87771660c975"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<ul>
<li>A Medication Guide and Warning Card that provide information about recognition of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should be dispensed with each new prescription and refill. </li>
<li>Abacavir tablets may be taken with or without food.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_946b8c2e-aa5b-438c-97b9-af05d87a3c42"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Patients</h2>
<p class="First">The recommended oral dose of abacavir tablets for adults is 600 mg daily, administered as either 300 mg twice daily or 600 mg once daily, in combination with other antiretroviral agents.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="_175da327-6944-8672-16e7-876cccb9d5e6"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Patients</h2>
<p class="First">The recommended oral dose of abacavir oral solution in HIV-1-infected pediatric patients aged 3 months and older is 8 mg per kg twice daily (up to a maximum of 600 mg daily) in combination with other antiretroviral agents.</p>
<p>Abacavir is also available as a scored tablet for HIV-1-infected pediatric patients weighing greater than or equal to 14 kg for whom a solid dosage form is appropriate. Before prescribing abacavir tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow abacavir tablets, the oral solution formulation should be prescribed. The  recommended oral dosage of abacavir tablets for HIV-1-infected pediatric patients is presented in Table 1.</p>
<p><span class="Bold">Table 1. Dosing Recommendations for Abacavir Tablets in Pediatric Patients </span></p>
<table frame="box"><tbody class="Headless" align="center" valign="middle">
<tr class="Botrule First">
<th colspan="1" rowspan="2">Weight (kg)</th>
<th colspan="2"><span class="Bold"><span class="Bold">Twice-daily Dosing Regimen</span></span></th>
<th rowspan="2">Total Daily Dose</th>
</tr>
<tr valign="middle">
<td><span class="Bold">AM Dose</span></td>
<td rowspan="1" valign="middle"><span class="Bold">PM Dose</span></td>
</tr>
<tr>
<td>14 to &lt;20 </td>
<td>½ tablet (150 mg)</td>
<td rowspan="1">½ tablet (150 mg)</td>
<td>300 mg</td>
</tr>
<tr>
<td>≥20 to &lt;25</td>
<td>½ tablet (150 mg)</td>
<td rowspan="1">1 tablet (300 mg)</td>
<td>450 mg</td>
</tr>
<tr class="Last">
<td>≥25 </td>
<td>1 tablet (300 mg)</td>
<td rowspan="1">1 tablet (300 mg)</td>
<td>600 mg</td>
</tr>
</tbody></table>
<p><span class="Bold">Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Company’s ZIAGEN<span class="Sup">®</span> (abacavir sulfate) tablets and oral solution. However, due to ViiV Healthcare Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77feaa4f-f24b-4167-811e-fbbc5af95896"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The recommended dose of abacavir tablets in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 6) is 200 mg twice daily. To enable dose reduction, abacavir oral solution (10 mL twice daily) should be used for the treatment of these patients. The safety, efficacy, and pharmacokinetic properties of abacavir have not been established in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; therefore, abacavir tablets are contraindicated in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_626eab63-cbf9-49a0-aebe-998ecd111cb9"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Abacavir tablets are available containing abacavir sulfate equivalent to 300 mg of abacavir. </p>
<p>The 300 mg tablets are yellow, biconvex, functionally scored, modified capsule-shaped, film-coated tablets engraved with "APO" on one side and "AB" bisect "300" on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_45f72e52-431e-430b-90f1-5daf10bd17fb"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Abacavir  tablets are contraindicated in patients with:</p>
<ul>
<li>previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir or any other component of the products. NEVER restart abacavir tablets or any other abacavir-containing product following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, regardless of HLA-B*5701 status <span class="Italics">[see <a href="#i4i_warnings_precautions_id_4dd661bf-c313-414f-a2aa-9b6489876e7b">Warnings and Precautions (5.1)</a>, <a href="#i4i_adverse_effects_id_b03c877b-7741-46cb-a5c1-467beeac906a">Adverse Reactions (6)</a>]</span>.</li>
<li>moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span><span class="Italics"> [see <a href="#i4i_section_id_77feaa4f-f24b-4167-811e-fbbc5af95896">Dosage and Administration (2.3)</a>].</span>
</li>
</ul>
<p></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_4dd661bf-c313-414f-a2aa-9b6489876e7b"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></h2>
<p class="First">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been associated with abacavir tablets and other abacavir-containing products. Patients who carry the HLA-B*5701 allele are at high risk for experiencing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.           </p>
<p>HLA-B*5701-negative patients may develop a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. Regardless of HLA-B*5701 status, permanently discontinue abacavir if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible. </p>
<p>Important information on signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, as well as clinical management, is presented below. </p>
<p><span class="Bold Italics">Signs and Symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir is a multi-organ clinical syndrome usually characterized by a sign or symptom in 2 or more of the following groups.    </p>
<p>Group 1: Fever    </p>
<p>Group 2: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>     </p>
<p>Group 3: Gastrointestinal (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>)    </p>
<p>Group 4: Constitutional (including generalized <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or achiness)    </p>
<p>Group 5: Respiratory (including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>).</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir following the presentation of a single sign or symptom has been reported infrequently. </p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to abacavir was reported in approximately 8% of 2,670 subjects (n = 206) in nine clinical trials (range: 2% to 9%) with enrollment from November 1999 to February 2002. Data on time to onset and symptoms of suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> were collected on a detailed data collection module. The frequencies of symptoms are shown in Figure 1. Symptoms usually appeared within the first 6 weeks of treatment with abacavir, although the reaction may occur at any time during therapy. Median time to onset was 9 days; 89% appeared within the first 6 weeks; 95% of subjects reported symptoms from two or more of the five groups listed above.</p>
<p><span class="Bold">Figure 1. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>-related Symptoms Reported with Greater than or Equal to 10% Frequency in Clinical Trials (n = 206 Subjects)</span></p>
<p>                                       <img alt="figure-1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73ce0bc5-43e2-c57f-0a6a-bdaf9fbaa3c2&amp;name=figure-1.jpg"><p class="MultiMediaCaptionNotCentered"></p></p>
<p>Other less common signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> include <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, myolysis, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, abnormal chest x-ray findings (predominantly infiltrates, which can be localized), and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred in association with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. In one trial, four subjects (11%) receiving abacavir 600 mg once daily experienced  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> compared with zero subjects receiving abacavir 300 mg twice daily.  </p>
<p>Physical findings associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir in some patients include <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, mucous membrane lesions (<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcerations</span>), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. The <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> usually appears maculopapular or urticarial, but may be variable in appearance. There have been reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have occurred without <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.  </p>
<p>Laboratory abnormalities associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir in some patients include elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>. </p>
<p><span class="Bold Italics">Clinical Management of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></p>
<p>Discontinue abacavir as soon as a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is suspected. To minimize the risk of a life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, permanently discontinue abacavir if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, even when other diagnoses are possible (e.g., acute onset respiratory diseases such as <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, or <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>; <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>; or reactions to other medications).</p>
<p>Following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir, NEVER restart abacavir tablets or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </p>
<p>When therapy with abacavir has been discontinued for reasons other than symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>, and if reinitiation of abacavir tablets or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of abacavir to ensure that the patient did not have symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of abacavir.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> cannot be ruled out, DO NOT reintroduce abacavir tablets or any other abacavir-containing product. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</p>
<p>If symptoms consistent with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> are not identified, reintroduction can be undertaken with continued monitoring for symptoms of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Make patients aware that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> can occur with reintroduction of abacavir tablets or any other abacavir-containing product and that reintroduction of abacavir tablets or any other abacavir-containing product needs to be undertaken only if medical care can be readily accessed by the patient or others.</p>
<p><span class="Bold Italics">Risk Factor</span></p>
<p><span class="Italics">HLA-B*5701 Allele </span></p>
<p><span class="Italics"></span>Trials have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to abacavir. </p>
<p>CNA106030 (PREDICT-1), a randomized, double-blind trial, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> in abacavir-naive HIV-1-infected adults (n = 1,650). In this trial, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> from 7.8% (66 of 847) to 3.4% (27 of 803). Based on this trial, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele. </p>
<p>Screening for carriage of the HLA-B*5701 allele is recommended prior to initiating treatment with abacavir. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk. </p>
<p>Skin patch testing is used as a research tool and should not be used to aid in the clinical diagnosis of abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. </p>
<p>In any patient treated with abacavir, the clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> must remain the basis of clinical decision-making. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</p>
<p><span class="Underline"></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c829b3a3-8657-4da8-aebe-5df2726c86e9"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</h2>
<p class="First"><span class="None"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including abacavir and other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering abacavir to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with abacavir should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0856894-9c54-42f6-b3a1-684c51768788"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including abacavir. During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> [PCP], or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment. </p>
<p><span class="None"><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Graves’ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_917c3387-e958-44f6-ad3c-60cf15a55fb1"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and “cushingoid appearance? have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac469e83-1415-4293-8c3a-231e8b034ca5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">In a published prospective, observational, epidemiological trial designed to investigate the rate of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in patients on combination antiretroviral therapy, the use of abacavir within the previous 6 months was correlated with an increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI)<span class="Sup">1</span>. In a sponsor-conducted pooled analysis of clinical trials, no excess risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was observed in abacavir-treated subjects as compared with control subjects. In totality, the available data from the observational cohort and from clinical trials are inconclusive.</p>
<p>As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus,  smoking). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_d2301bbf-db0f-0bc1-247d-84f3d79eca66"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Use with Other Abacavir-containing Products</h2>
<p class="First">Abacavir tablets are one of multiple abacavir-containing products. Concomitant administration of abacavir tablets with other products containing abacavir is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_b03c877b-7741-46cb-a5c1-467beeac906a"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<p></p>
<ul>
<li>Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. In one trial, once-daily dosing of abacavir was associated with more severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> <span class="Italics">[see</span> <span class="Italics"><a href="#id_9c52baa5-0e88-4758-855f-4cfdfb325aa0">Boxed Warning</a>, <a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696"> Warnings and Precautions </a></span><a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696"></a><span class="Italics"><a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696">(5.1)</a></span><span class="Italics">]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> <span class="Italics">[see</span> <span class="Italics"><a href="#id_9c52baa5-0e88-4758-855f-4cfdfb325aa0">Boxed Warning</a></span>, <span class="Italics"><a href="#i4i_section_id_c829b3a3-8657-4da8-aebe-5df2726c86e9">Warnings and Precautions (5.2)</a></span><span class="Italics">]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> <span class="Italics">[see</span> <span class="Italics"><a href="#i4i_section_id_d0856894-9c54-42f6-b3a1-684c51768788">Warnings and Precautions (5.3)</a></span><span class="Italics">]</span>.</li>
<li>Fat redistribution <span class="Italics">[see</span> <span class="Italics"><a href="#i4i_section_id_917c3387-e958-44f6-ad3c-60cf15a55fb1">Warnings and Precautions (5.4)</a></span><span class="Italics">]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> <span class="Italics">[see </span><span class="Italics"><a href="#i4i_section_id_ac469e83-1415-4293-8c3a-231e8b034ca5">Warnings and Precautions (5.5)</a><span class="Italics">]</span></span>. </li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="_0ee1b957-748b-db19-def6-e3c4956f37e7"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience in Adult Subjects</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold"></span><span class="Italics">Therapy-naïve Adults</span><br><span class="Italics"></span>Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a greater than or equal to 5% frequency during therapy with abacavir 300 mg twice daily, lamivudine 150 mg twice daily, and efavirenz 600 mg daily compared with zidovudine 300 mg twice daily, lamivudine 150 mg twice daily, and efavirenz 600 mg daily from CNA30024 are listed in Table 2.</p>
<table width="0.000">
<caption><span>Table 2. Treatment-emergent (All Causality) Adverse Reactions of at Least Moderate Intensity (Grades 2 to 4, Greater than or Equal to 5% Frequency) in Therapy-naive Adults (CNA30024<span class="Sup">a</span>) through 48 Weeks of Treatment</span></caption>
<col>
<col>
<col>
<tfoot>
<tr class="First"><td align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">a</span> This trial used double-blind ascertainment of suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. During the blinded portion of the trial, suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir was reported by investigators in 9% of 324 subjects in the abacavir group and 3% of 325 subjects in the zidovudine group.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">b</span> Ten (3%) cases of suspected <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> were reclassified as not being due to abacavir following unblinding.</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="1" valign="middle"><span class="Bold"> Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Abacavir plus Lamivudine plus Efavirenz</span><span class="Bold"><br>(n = 324)</span>
</td>
<td class="Botrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Zidovudine plus Lamivudine plus Efavirenz</span><span class="Bold"><br>(n = 325)</span>
</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Dreams/<span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">Drug hypersensitivity</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">9%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">&lt;1%<span class="Sup">b</span></p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span>/<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">7%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">11%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">7%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">11%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">7%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">7%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>/<span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>/<br>gastrointestinal signs and symptoms</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorders</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">4%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="top"><p class="First">2%</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">9%</p></td>
</tr>
</tbody>
</table>
<p>Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a greater than or equal to 5% frequency during therapy with abacavir 300 mg twice daily, lamivudine 150 mg twice daily, and zidovudine 300 mg twice daily compared with indinavir 800 mg 3 times daily, lamivudine 150 mg twice daily, and zidovudine 300 mg twice daily from CNA3005 are listed in Table 3.</p>
<table width="0.000">
<caption><span>Table 3. Treatment-emergent (All Causality) Adverse Reactions of at Least Moderate Intensity (Grades 2 to 4, Greater than or Equal to 5% Frequency) in Therapy-naive Adults (CNA3005) through 48 Weeks of Treatment</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="1" valign="middle"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Abacavir plus Lamivudine/Zidovudine</span><span class="Bold"><br>(n = 262)</span>
</td>
<td class="Botrule" align="center" rowspan="1" valign="top">
<span class="Bold">Indinavir plus Lamivudine/Zidovudine</span><span class="Bold"><br>(n = 264)</span>
</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">19%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">17%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">13%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">9%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">12%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">12%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reaction</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">8%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">7%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive disorders</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Ear/nose/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Viral <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Renal signs/symptoms</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">&lt;1%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (non-site-specific)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">&lt;1%</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
</tbody>
</table>
<p>Five subjects receiving abacavir in CNA3005 experienced worsening of pre-existing <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> compared with none in the indinavir arm. The background rates of pre-existing <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were similar in the two treatment arms.</p>
<p><span class="Bold Italics">Abacavir Once Daily versus Abacavir Twice Daily (CNA30021)</span><br>Treatment-emergent clinical adverse reactions (rated by the investigator as at least moderate) with a greater than or equal to 5% frequency during therapy with abacavir 600 mg once daily or abacavir 300 mg twice daily, both in combination with lamivudine 300 mg once daily and efavirenz 600 mg once daily from CNA30021, were similar. For <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, subjects receiving abacavir once daily showed a rate of 9% in comparison with a rate of 7% for subjects receiving abacavir twice daily. However, subjects receiving abacavir 600 mg once daily experienced a significantly higher incidence of severe <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions and severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> compared with subjects who received abacavir 300 mg twice daily. Five percent (5%) of subjects receiving abacavir 600 mg once daily had severe <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions compared with 2% of subjects receiving abacavir 300 mg twice daily. Two percent (2%) of subjects receiving abacavir 600 mg once daily had severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> while none of the subjects receiving abacavir 300 mg twice daily had this event. </p>
<p><span class="Bold Italics">Laboratory Abnormalities</span><br>Laboratory abnormalities (Grades 3 to 4) in therapy-naive adults during therapy with abacavir 300 mg twice daily, lamivudine 150 mg twice daily, and efavirenz 600 mg daily compared with zidovudine 300 mg twice daily, lamivudine 150 mg twice daily, and efavirenz 600 mg daily from CNA30024 are listed in Table 4.</p>
<table width="0.000">
<caption><span>Table 4. Laboratory Abnormalities (Grades 3 to 4) in Therapy-naive Adults (CNA30024) through 48 Weeks of Treatment</span></caption>
<col>
<col>
<col>
<tfoot>
<tr class="First"><td align="left" colspan="3" rowspan="1" valign="top"><p class="First">ULN = Upper limit of normal.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top"><p class="First">n = Number of subjects assessed.</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="1" valign="middle">
<span class="Bold">Grade 3/4 </span><span class="Bold"><br>Laboratory Abnormalities</span>
</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Abacavir plus</span> <span class="Bold">Lamivudine plus Efavirenz</span><br><span class="Bold">(n = 324)</span>
</td>
<td class="Botrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Zidovudine plus </span><span class="Bold">Lamivudine plus Efavirenz<br>(n = 325)</span>
</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Elevated CPK (&gt;4 X ULN)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">8%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">8%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Elevated ALT (&gt;5 X ULN)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Elevated AST (&gt;5 X ULN)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (&gt;750 mg/dL)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">6%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Hyperamylasemia (&gt;2 X ULN)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">4%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (ANC &lt;750/mm<span class="Sup">3</span>)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">2%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb ≤6.9 gm/dL)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">&lt;1%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (Platelets &lt;50,000/mm<span class="Sup">3</span>)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">1%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">&lt;1%</p></td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> (WBC ≤1,500/mm<span class="Sup">3</span>)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">&lt;1%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">2%</p></td>
</tr>
</tbody>
</table>
<p>Laboratory abnormalities in CNA3005 are listed in Table 5.</p>
<table width="432.000">
<caption><span>Table 5. Treatment-emergent Laboratory Abnormalities (Grades 3 to 4) in CNA3005 </span></caption>
<col width="33.3%">
<col width="33.3%">
<col width="33.3%">
<tfoot>
<tr class="First"><td align="left" colspan="3" rowspan="1" valign="top"><p class="First">ULN = Upper limit of normal.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" valign="top"><p class="First">n = Number of subjects assessed.</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Grade 3/4 Laboratory Abnormalities</span></td>
<td class="Botrule" align="center" colspan="2" rowspan="1" valign="middle"><span class="Bold">Number of Subjects by Treatment Group</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="1" valign="top">
<span class="Bold">Abacavir plus</span><br><span class="Bold">Lamivudine/Zidovudine</span><span class="Bold">(n = 262)</span>
</td>
<td class="Botrule" align="center" rowspan="1" valign="bottom">
<span class="Bold">Indinavir plus Lamivudine/Zidovudine</span><span class="Bold">(n = 264)</span>
</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Elevated CPK (&gt;4 x ULN)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">18 (7%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">18 (7%)</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">ALT (&gt;5.0 x ULN)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">16 (6%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">16 (6%)</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt;750/mm<span class="Sup">3</span>)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">13 (5%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">13 (5%)</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> (&gt;750 mg/dL)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">5 (2%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">3 (1%)</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Hyperamylasemia (&gt;2.0 x ULN)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">5 (2%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">1 (&lt;1%)</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> (&gt;13.9 mmol/L)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">2 (&lt;1%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">2 (&lt;1%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb ≤6.9 g/dL)</p></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="top"><p class="First">0 (0%)</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">3 (1%)</p></td>
</tr>
</tbody>
</table>
<p>The frequencies of treatment-emergent laboratory abnormalities were comparable between treatment groups in CNA30021.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_53714907-4bdd-0a07-8789-63ea3e451762"></a><a name="section-6.2"></a><p></p>
<h2>6.2 <span class="None"> Clinical Trials Experience in Pediatric Subjects</span>
</h2>
<p class="First"><span class="Bold Italics">Therapy-experienced Pediatric Subjects <span class="Italics"><span class="Bold Italics"> (Twice-daily Dosing)</span></span></span><br><span class="Italics"></span>Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a greater than or equal to 5% frequency during therapy with abacavir 8 mg per kg twice daily, lamivudine 4 mg per kg twice daily, and zidovudine 180 mg per m<span class="Sup">2</span> twice daily compared with lamivudine 4 mg per kg twice daily and zidovudine 180 mg per m<span class="Sup">2</span> twice daily from CNA3006 are listed in Table 6. </p>
<table width="0.000">
<caption><span>Table 6. Treatment-emergent (All Causality) Adverse Reactions of at Least Moderate Intensity (Grades 2 to 4, Greater than or Equal to 5% Frequency) in Therapy-experienced Pediatric Subjects (CNA3006) through 16 Weeks of Treatment</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="1" valign="middle"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Abacavir plus Lamivudine plus Zidovudine</span><br><span class="Bold">(n = 102)</span>
</td>
<td class="Botrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Lamivudine plus Zidovudine</span><br><span class="Bold">(n = 103)</span>
</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">9%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">9%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">7%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Ear/nose/<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">4%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" rowspan="1" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">1%</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">5%</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold Italics">Laboratory Abnormalities</span><br><span class="Italics"></span>In CNA3006, laboratory abnormalities (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, liver function test abnormalities, and CPK elevations) were observed with similar frequencies as in a trial of therapy-naive adults (CNA30024). Mild elevations of blood glucose were more frequent in pediatric subjects receiving abacavir (CNA3006) as compared with adult subjects (CNA30024).</p>
<p><span class="Bold Italics">Other Adverse Events </span><br>In addition to adverse reactions and laboratory abnormalities reported in Tables 2, 3, 4, 5, and 6, other adverse reactions observed in the expanded access program were <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and increased GGT.</p>
<p><span class="Bold">Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Company’s ZIAGEN<span class="Sup">® </span>(abacavir sulfate) tablets and oral solution. However, due to ViiV Healthcare Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c064dd0d-c13e-4932-a37f-a8ce73967cbf"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of abacavir. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposures. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to abacavir.  </p>
<p><span class="Bold Italics">Body as a Whole </span><br>Redistribution/accumulation of body fat.</p>
<p><span class="Bold Italics">Cardiovascular </span><br><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span>.</p>
<p><span class="Bold Italics">Hepatic </span><br><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>.</p>
<p><span class="Bold Italics">Skin</span><br>Suspected <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS) and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN) have been reported in patients receiving abacavir primarily in combination with medications known to be associated with SJS and TEN, respectively. Because of the overlap of clinical signs and symptoms between <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to abacavir and SJS and TEN, and the possibility of multiple drug sensitivities in some patients, abacavir should be discontinued and not restarted in such cases.</p>
<p>There have also been reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> with abacavir use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_4027d158-f870-4936-b076-62c061e66862"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="_f6174652-918f-ea16-5502-a8909f6a7c6f"></a><a name="section-7.1"></a><p></p>
<h2>
         7.1 Ethanol
      
   </h2>
<p class="First"><span class="Bold"></span>Abacavir has no effect on the pharmacokinetic properties of ethanol. Ethanol decreases the elimination of abacavir causing an increase in overall exposure <span class="Italics">[see </span><span class="Italics"><a href="#i4i_pharmacokinetics_id_6451f77d-43ca-4bd0-9712-fc4e504c45c7">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_0bcc72e2-f624-baad-24b3-fd70a3d4f886"></a><a name="section-7.2"></a><p></p>
<h2>
      7.2 Methadone
   </h2>
<p class="First"><span class="Bold"></span>The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. In a trial of 11 HIV-1-infected subjects receiving methadone-maintenance therapy with 600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased <span class="Italics">[see </span><span class="Italics"><a href="#i4i_pharmacokinetics_id_6451f77d-43ca-4bd0-9712-fc4e504c45c7">Clinical Pharmacology (12.3)</a></span><span class="Italics">]</span>. This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_19dcc5a8-262a-4629-bfa8-e4bed7cf5d9a"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_9747dbd6-fe29-4e0a-a5de-27b369782576"></a><a name="section-8.1"></a><p></p>
<h2><span class="None">8.1 Pregnancy </span></h2>
<p class="First"><span class="Bold Italics">Pregnancy Exposure Registry</span><br>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir during pregnancy. Physicians are encouraged to register patients by calling the Antiretroviral Pregnancy Registry at 1-800-258-4263.</p>
<p><span class="Bold Italics">Risk Summary</span><br>Available data from the Antiretroviral Pregnancy Registry show no difference in the risk of overall major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> for abacavir compared with the background rate for major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> of 2.7% in the US reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). Abacavir produced <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> and other embryonic and fetal toxicities in rats at 35 times the human exposure at the recommended clinical dose. The relevance of animal findings to human pregnancy registry data is not known.</p>
<p><span class="Bold Italics">Data</span></p>
<p><span class="Italics">Human Data</span><br>Based on prospective reports from the Antiretroviral Pregnancy Registry of over 2,000 exposures to abacavir during pregnancy resulting in live births (including over 900 exposed in the first trimester), there was no difference between abacavir and overall <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> compared with the background birth defect rate of 2.7% in the US reference population of the MACDP. The prevalence of defects in the first trimester was 3.0% (95% CI: 2.0% to 4.4%).</p>
<p><span class="Italics">Animal Data</span><br>Studies in pregnant rats showed that abacavir is transferred to the fetus through the placenta. <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">Fetal malformations</span> (increased incidences of fetal <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span> and skeletal malformations) and developmental toxicity (depressed fetal body weight and reduced crown-rump length) were observed in rats at a dose which produced 35 times the human exposure based on AUC. Embryonic and fetal toxicities (increased resorptions, decreased fetal body weights) and toxicities to the offspring (increased incidence of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span> and lower body weights) occurred at half of the above-mentioned dose in separate fertility studies conducted in rats. In the rabbit, no developmental toxicity and no increases in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> occurred at doses that produced 8.5 times the human exposure at the recommended dose based on AUC.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_34b1f397-75cf-48d4-9b03-a92c3fce4ac3"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Lactation</h2>
<p class="First"><span class="Bold Italics">Risk Summary</span><br>The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking postnatal transmission of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Because of the potential for HIV-1 transmission, mothers should be instructed not to breastfeed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_39e2ce9f-834e-468c-a90d-ebfdbc976169"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of abacavir have been established in pediatric patients aged 3 months and older. Use of abacavir is supported by pharmacokinetic trials and evidence from adequate and well-controlled trials of abacavir in adults and pediatric subjects <span class="Italics">[see <a href="#_175da327-6944-8672-16e7-876cccb9d5e6"> Dosage and Administration (2.2)</a>, <a href="#_53714907-4bdd-0a07-8789-63ea3e451762"> Adverse Reactions (6.2)</a>, <a href="#i4i_pharmacokinetics_id_6451f77d-43ca-4bd0-9712-fc4e504c45c7"> Clinical Pharmacology (12.3)</a>, <a href="#i4i_section_id_ceedef33-bcda-48f8-be95-8e7113e9ce1a"> Clinical Studies (14.2)</a>].</span> </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_d3733fcb-20f8-40f0-b25a-5471bae23d00"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of abacavir did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_845a0509-fe30-4b95-9395-d8cbb367c6a2"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no known antidote for abacavir. It is not known whether abacavir can be removed by peritoneal dialysis or hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_fb5cde43-f630-4088-8bcf-665be0970f5a"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Abacavir sulfate is a synthetic carbocyclic nucleoside analogue with inhibitory activity against HIV-1. The chemical name of abacavir sulfate is <span class="Italics">(</span>1<span class="Italics">S,cis)-</span>4-[2-amino-6-(cyclopropylamino)-9<span class="Italics">H</span>-purin-9-yl]-2-cyclopentene-1-methanol sulfate (salt) (2:1). Abacavir sulfate is the enantiomer with <span class="Italics">1S</span>, <span class="Italics">4R</span> absolute configuration on the cyclopentene ring. It has a molecular formula of (C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">6</span>O)<span class="Sub">2</span>•H<span class="Sub">2</span>SO<span class="Sub">4 </span>and a molecular weight of 670.76 daltons. It has the following structural formula:</p>
<p>                                                      <img alt="structural-formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73ce0bc5-43e2-c57f-0a6a-bdaf9fbaa3c2&amp;name=structural-formula.jpg"></p>
<p>Abacavir sulfate, USP is a white to off-white solid with a solubility of approximately 77 mg per mL in distilled water at 25°C. It has an octanol per water (pH 7.1 to 7.3) partition coefficient (log <span class="Italics">P</span>) of approximately 1.20 at 25°C. </p>
<p>Abacavir tablets, USP are for oral administration. Each tablet contains abacavir sulfate, USP equivalent to 300 mg of abacavir as active ingredient and the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and croscarmellose sodium. The tablets are coated with a film that is made of hypromellose, polyethylene glycol, yellow iron oxide, and titanium dioxide.</p>
<p><span class="Italics">In vivo</span>, abacavir sulfate dissociates to its free base, abacavir. All dosages for abacavir tablets are expressed in terms of abacavir.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_3b34aefd-5311-4c8b-9141-b0437190a4a1"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_71edebfb-042d-4113-bc18-797a1c81d1b6"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Abacavir is an antiviral agent <span class="Italics">[see<a href="#i4i_section_id_0d915bee-7363-4d25-836f-9c028de415a2"> Microbiology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_6451f77d-43ca-4bd0-9712-fc4e504c45c7"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold Italics">Pharmacokinetics in Adults </span><br>The pharmacokinetic properties of abacavir have been studied in asymptomatic, HIV-1-infected adult subjects after administration of a single intravenous (IV) dose of 150 mg and after single and multiple oral doses. The pharmacokinetic properties of abacavir were independent of dose over the range of 300 to 1,200 mg per day.</p>
<p><span class="Bold Italics">Absorption and Bioavailability</span><br>Abacavir was rapidly and extensively absorbed after oral administration. The geometric mean absolute bioavailability of the tablet was 83%. Plasma abacavir AUC was similar following administration of the oral solution or tablets. After oral administration of 300 mg twice daily in 20 subjects, the steady-state peak serum abacavir concentration (C<span class="Sub">max</span>) was 3.0 ± 0.89 mcg per mL (mean ± SD) and AUC<span class="Sub">(0 to 12 h)</span> was 6.02 ± 1.73 mcg•hour per mL. After oral administration of a single dose of 600 mg of abacavir in 20 subjects, C<span class="Sub">max</span> was 4.26 ± 1.19 mcg per mL (mean ± SD) and AUC<span class="Sub">∞</span> was 11.95 ± 2.51 mcg•hour per mL.</p>
<p><span class="Bold Italics">Distribution</span><br>The apparent volume of distribution after IV administration of abacavir was 0.86 ± 0.15 L per kg, suggesting that abacavir distributes into extravascular space. In 3 subjects, the CSF AUC<span class="Sub"> (0 to 6 h)</span> to plasma abacavir AUC<span class="Sub"> (0 to 6 h)</span> ratio ranged from 27% to 33%.</p>
<p>Binding of abacavir to human plasma proteins is approximately 50%. Binding of abacavir to plasma proteins was independent of concentration. Total blood and plasma drug-related radioactivity concentrations are identical, demonstrating that abacavir readily distributes into erythrocytes.</p>
<p><span class="Bold Italics">Metabolism</span><br>In humans, abacavir is not significantly metabolized by cytochrome P450 enzymes. The primary routes of elimination of abacavir are metabolism by alcohol dehydrogenase (to form the 5′-carboxylic acid) and glucuronyl transferase (to form the 5′-glucuronide). The metabolites do not have antiviral activity. <span class="Italics">In vitro</span> experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.</p>
<p><span class="Bold Italics">Elimination</span><br>Elimination of abacavir was quantified in a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance trial following administration of a 600-mg dose of <span class="Sup">14</span>C-abacavir: 99% of the radioactivity was recovered, 1.2% was excreted in the urine as abacavir, 30% as the 5′-carboxylic acid metabolite, 36% as the 5′-glucuronide metabolite, and 15% as unidentified minor metabolites in the urine. Fecal elimination accounted for 16% of the dose.</p>
<p>In single-dose trials, the observed elimination half-life (t<span class="Sub">1/2</span>) was 1.54 ± 0.63 hours. After intravenous administration, total clearance was 0.80 ± 0.24 L per hour per kg (mean ± SD). </p>
<p><span class="Bold Italics">Effects of Food on Oral Absorption </span><br>Bioavailability of abacavir tablets was assessed in the fasting and fed states. There was no significant difference in systemic exposure (AUC<span class="Sub">∞</span>) in the fed and fasting states; therefore, abacavir tablets may be administered with or without food. Systemic exposure to abacavir was comparable after administration of abacavir oral solution and abacavir tablets. Therefore, these products may be used interchangeably.</p>
<p><span class="Bold Italics">Special Populations </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><br><span class="Italics"></span>The pharmacokinetic properties of abacavir have not been determined in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Renal excretion of unchanged abacavir is a minor route of elimination in humans. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span><br><span class="Italics"></span>The pharmacokinetics of abacavir have been studied in subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 5 to 6). Results showed that there was a mean increase of 89% in the abacavir AUC and an increase of 58% in the half-life of abacavir after a single dose of 600 mg of abacavir. The AUCs of the metabolites were not modified by mild liver disease; however, the rates of formation and elimination of the metabolites were decreased. A dose of 200 mg (provided by 10 mL of abacavir oral solution) administered twice daily is recommended for patients with mild liver disease. The safety, efficacy, and pharmacokinetics of abacavir have not been studied in subjects with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; therefore, abacavir is contraindicated in these patients.</p>
<p><span class="Italics">Pediatric Patients </span><br>The pharmacokinetics of abacavir have been studied after either single or repeat doses of abacavir in pediatric subjects. Subjects receiving abacavir oral solution according to the recommended dosage regimen achieved plasma concentrations of abacavir similar to adults. Subjects receiving abacavir oral tablets achieved higher plasma concentrations of abacavir than subjects receiving oral solution.</p>
<p><span class="Bold">Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Company’s ZIAGEN<span class="Sup">®</span> (abacavir sulfate) tablets and oral solution. However, due to ViiV Healthcare Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
<p><span class="Italics">Geriatric Patients </span><br>The pharmacokinetics of abacavir have not been studied in subjects over 65 years of age. </p>
<p><span class="Italics">Gender </span><br><span class="Italics"></span>A population pharmacokinetic analysis in HIV-1-infected male (n = 304) and female (n = 67) subjects showed no gender differences in abacavir AUC normalized for lean body weight.</p>
<p><span class="Italics">Race </span><br>There are no significant differences between blacks and whites in abacavir pharmacokinetics. </p>
<p><span class="Bold Italics">Drug Interactions </span></p>
<p>In human liver microsomes, abacavir did not inhibit cytochrome P450 isoforms (2C9, 2D6, 3A4). Based on these data, it is unlikely that clinically significant drug interactions will occur between abacavir and drugs metabolized through these pathways. </p>
<p><span class="Italics">Lamivudine and/or Zidovudine </span><br><span class="Italics"></span>Due to the common metabolic pathways of abacavir and zidovudine via glucuronyl transferase, 15 HIV-1-infected subjects were enrolled in a crossover trial evaluating single doses of abacavir (600 mg), lamivudine (150 mg), and zidovudine (300 mg) alone or in combination. Analysis showed no clinically relevant changes in the pharmacokinetics of abacavir with the addition of lamivudine or zidovudine or the combination of lamivudine and zidovudine. Lamivudine exposure (AUC decreased 15%) and zidovudine exposure (AUC increased 10%) did not show clinically relevant changes with concurrent abacavir.</p>
<p><span class="Italics">Ethanol </span><br>Due to the common metabolic pathways of abacavir and ethanol via alcohol dehydrogenase, the <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between abacavir and ethanol was studied in 24 HIV-1-infected male subjects. Each subject received the following treatments on separate occasions: a single 600 mg dose of abacavir, 0.7 g per kg ethanol (equivalent to five alcoholic drinks), and abacavir 600 mg plus 0.7 g per kg ethanol. Coadministration of ethanol and abacavir resulted in a 41% increase in abacavir AUC<span class="Sub">∞</span> and a 26% increase in abacavir t<span class="Sub">1/2</span>. In males, abacavir had no effect on the pharmacokinetic properties of ethanol, so no clinically significant interaction is expected in men. This interaction has not been studied in females.</p>
<p><span class="Italics">Methadone </span><br><span class="Italics"></span>In a trial of 11 HIV-1-infected subjects receiving methadone-maintenance therapy (40 mg and 90 mg daily), with 600 mg of abacavir twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI: 6% to 42%). This alteration will not result in a methadone dose modification in the majority of patients; however, an increased methadone dose may be required in a small number of patients. The addition of methadone had no clinically significant effect on the pharmacokinetic properties of abacavir.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_section_id_0d915bee-7363-4d25-836f-9c028de415a2"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5′-triphosphate (dGTP). CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. The lack of a 3′-OH group in the incorporated nucleotide analogue prevents the formation of the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. CBV-TP is a weak inhibitor of cellular DNA polymerases α, β, and γ.</p>
<p><span class="Bold Italics">Antiviral Activity </span><br>The antiviral activity of abacavir against HIV-1 was evaluated against a T-cell tropic laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> HIV-1<span class="Sub">IIIB</span> in lymphoblastic cell lines, a monocyte/macrophage tropic laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> HIV-1<span class="Sub">BaL</span> in primary monocytes/macrophages, and clinical isolates in peripheral blood mononuclear cells. The concentration of drug necessary to effect viral replication by 50 percent (EC<span class="Sub">50</span>) ranged from 3.7 to 5.8 mcM (1 mcM = 0.28 mcg per mL) and 0.07 to 1.0 mcM against HIV-1<span class="Sub">IIIB</span> and HIV-1<span class="Sub">BaL</span>, respectively, and was 0.26 ± 0.18 mcM against eight clinical isolates. The EC<span class="Sub">50</span> values of abacavir against different HIV-1 clades (A-G) ranged from 0.0015 to 1.05 mcM, and against HIV-2 isolates, from 0.024 to 0.49 mcM. The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir. Ribavirin (50 mcM) had no effect on the anti–HIV-1 activity of abacavir in cell culture.</p>
<p><span class="Bold Italics">Resistance </span><br>HIV-1 isolates with reduced susceptibility to abacavir have been selected in cell culture and were also obtained from subjects treated with abacavir. Genotypic analysis of isolates selected in cell culture and recovered from abacavir-treated subjects demonstrated that amino acid substitutions K65R, L74V, Y115F, and M184V/I in RT contributed to abacavir resistance. In a trial of therapy-naive adults receiving abacavir 600 mg once daily (n = 384) or 300 mg twice daily (n = 386), in a background regimen of lamivudine 300 mg once daily and efavirenz 600 mg once daily (CNA30021), the incidence of virologic failure at 48 weeks was similar between the 2 groups (11% in both arms). Genotypic (n = 38) and phenotypic analyses (n = 35) of virologic failure isolates from this trial showed that the RT substitutions that emerged during abacavir once-daily and twice-daily therapy were K65R, L74V, Y115F, and M184V/I. The substitution M184V/I was the most commonly observed substitution in virologic failure isolates from subjects receiving abacavir once daily (56%, 10 of 18) and twice daily (40%, 8 of 20).</p>
<p>Thirty-nine percent (7 of 18) of the isolates from subjects who experienced virologic failure in the abacavir once-daily arm had a greater than 2.5-fold decrease in abacavir susceptibility with a median-fold decrease of 1.3 (range: 0.5 to 11) compared with 29% (5 of 17) of the failure isolates in the twice-daily arm with a median-fold decrease of 0.92 (range: 0.7 to 13).</p>
<p><span class="Bold Italics">Cross-resistance </span><br>Cross-resistance has been observed among NRTIs. Isolates containing abacavir resistance-associated substitutions, namely, K65R, L74V, Y115F, and M184V, exhibited cross-resistance to didanosine, emtricitabine, lamivudine, tenofovir, and zalcitabine in cell culture and in subjects. The K65R substitution can confer resistance to abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zalcitabine; the L74V substitution can confer resistance to abacavir, didanosine, and zalcitabine; and the M184V substitution can confer resistance to abacavir, didanosine, emtricitabine, lamivudine, and zalcitabine. An increasing number of thymidine analogue mutations (TAMs: M41L, D67N, K70R, L210W, T215Y/F, K219E/R/H/Q/N) is associated with a progressive reduction in abacavir susceptibility.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_286ac579-d93c-4202-adf6-95b3d2e5bddb"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_842de6a5-38c1-47fe-b8ba-c4f8cd57368d"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold Italics">Carcinogenicity </span></p>
<p>Abacavir was administered orally at three dosage levels to separate groups of mice and rats in 2-year carcinogenicity studies. Results showed an increase in the incidence of malignant and non-<span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span>. <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">Malignant tumors</span> occurred in the preputial gland of males and the clitoral gland of females of both species, and in the liver of female rats. In addition, non-<span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> also occurred in the liver and thyroid gland of female rats. These observations were made at systemic exposures in the range of 6 to 32 times the human exposure at the recommended dose. It is not known how predictive the results of rodent carcinogenicity studies may be for humans. </p>
<p><span class="Bold Italics">Mutagenicity </span></p>
<p>Abacavir induced chromosomal aberrations both in the presence and absence of metabolic activation in an <span class="Italics">in vitro</span> cytogenetic study in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Abacavir was mutagenic in the absence of metabolic activation, although it was not mutagenic in the presence of metabolic activation in an L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay. Abacavir was clastogenic in males and not clastogenic in females in an <span class="Italics">in vivo</span> mouse bone marrow micronucleus assay. Abacavir was not mutagenic in bacterial mutagenicity assays in the presence and absence of metabolic activation. </p>
<p><span class="Bold Italics">Impairment of Fertility </span></p>
<p>Abacavir had no adverse effects on the mating performance or fertility of male and female rats at a dose approximately 8 times the human exposure at the recommended dose based on body surface area comparisons. </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_d8e53c6a-9b2a-44cf-afb9-e73f203ad2fe"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Myocardial degeneration</span> was found in mice and rats following administration of abacavir for 2 years. The systemic exposures were equivalent to 7 to 24 times the expected systemic exposure in humans. The clinical relevance of this finding has not been determined.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_9d574162-b56c-460e-a458-2f6892f5a80e"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4626742b-239f-4773-bcd4-cd2197aad45f"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adult Trials</h2>
<p class="First"><span class="Bold Italics">Therapy-naive Adults <br></span>CNA30024 was a multicenter, double-blind, controlled trial in which 649 HIV-1-infected, therapy-naive adults were randomized and received either abacavir (300 mg twice daily), lamivudine (150 mg twice daily), and efavirenz (600 mg once daily); or zidovudine (300 mg twice daily), lamivudine (150 mg twice daily), and efavirenz (600 mg once daily). The duration of double-blind treatment was at least 48 weeks. Trial participants were male (81%), white (51%), black (21%), and Hispanic (26%). The median age was 35 years; the median pretreatment CD4+ cell count was 264 cells per mm<span class="Sup">3</span>, and median plasma HIV-1 RNA was 4.79 log<span class="Sub">10</span> copies per mL. The outcomes of randomized treatment are provided in Table 7.</p>
<a name="id_956a7ad9-b256-42b2-a096-c697c20c2081"></a><table width="0.000">
<caption><span>Table 7. Outcomes of Randomized Treatment through Week 48 (CNA30024) </span></caption>
<col>
<col>
<col>
<tfoot>
<tr><td class="Lrule Rrule" align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">a</span> Subjects achieved and maintained confirmed HIV-1 RNA less than or equal to 50 copies per mL (less than 400 copies per mL) through Week 48 (Roche AMPLICOR Ultrasensitive HIV-1 MONITOR<span class="Sup">®</span> standard test 1.0 PCR).</p></td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">b</span> Includes viral rebound, insufficient viral response according to the investigator, and failure to achieve confirmed less than or equal to 50 copies per mL by Week 48.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">c</span> Includes consent withdrawn, lost to follow up, protocol violations, those with missing data, clinical progression, and other.</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="1" valign="middle"><span class="Bold">Outcome</span></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Abacavir plus Lamivudine plus Efavirenz</span><br><span class="Bold">(n = 324)</span>
</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Zidovudine plus Lamivudine plus Efavirenz</span><br><span class="Bold">(n = 325)</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top"><p class="First">Responder<span class="Sup">a</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"><p class="First">69% (73%)</p></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"><p class="First">69% (71%)</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top"><p class="First">Virologic failures<span class="Sup">b</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"><p class="First">6%</p></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"><p class="First">4%</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top"><p class="First">Discontinued due to adverse reactions</p></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"><p class="First">14%</p></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"><p class="First">16%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" rowspan="1" valign="top"><p class="First">Discontinued due to other reasons<span class="Sup">c</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom"><p class="First">10%</p></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom"><p class="First">11%</p></td>
</tr>
</tbody>
</table>
<p>After 48 weeks of therapy, the median CD4+ cell count increases from baseline were 209 cells per mm<span class="Sup">3</span> in the group receiving abacavir and 155 cells per mm<span class="Sup">3</span> in the zidovudine group. Through Week 48, eight subjects (2%) in the group receiving abacavir (five CDC classification C events and three <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) and five subjects (2%) on the zidovudine arm (three CDC classification C events and two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) experienced clinical disease progression.</p>
<p>CNA3005 was a multicenter, double-blind, controlled trial in which 562 HIV-1-infected, therapy-naive adults were randomized to receive either abacavir (300 mg twice daily) plus COMBIVIR<span class="Sup">®</span> (lamivudine 150 mg/zidovudine 300 mg twice daily), or indinavir (800 mg 3 times a day) plus COMBIVIR twice daily. The trial was stratified at randomization by pre-entry plasma HIV-1 RNA 10,000 to 100,000 copies per mL and plasma HIV-1 RNA greater than 100,000 copies per mL. Trial participants were male (87%), white (73%), black (15%), and Hispanic (9%). At baseline the median age was 36 years; the median baseline CD4+ cell count was 360 cells per mm<span class="Sup">3</span>, and median baseline plasma HIV-1 RNA was 4.8 log<span class="Sub">10</span> copies per mL. Proportions of subjects with plasma HIV-1 RNA less than 400 copies per mL (using Roche AMPLICOR HIV-1 MONITOR Test) through 48 weeks of treatment are summarized in Table 8.</p>
<a name="id_f2c18711-c06f-41bf-bdcb-603abed30cd4"></a><table width="0.000">
<caption><span>Table 8. Outcomes of Randomized Treatment through Week 48 (CNA3005)</span></caption>
<col>
<col>
<col>
<tfoot>
<tr><td align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">a</span> Subjects achieved and maintained confirmed HIV-1 RNA less than 400 copies per mL.</p></td></tr>
<tr><td align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">b</span> Includes viral rebound and failure to achieve confirmed less than 400 copies per mL by Week 48. </p></td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">c</span> Includes consent withdrawn, lost to follow up, protocol violations, those with missing data, clinical progression, and other.</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="1" valign="middle"><span class="Bold">Outcome</span></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Abacavir plus Lamivudine/Zidovudine</span><br><span class="Bold">(n = 262)</span>
</td>
<td class="Botrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Indinavir plus </span><span class="Bold">Lamivudine/Zidovudine</span><br><span class="Bold">(n = 265)</span>
</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Responder<span class="Sup">a</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">49%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">50%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Virologic failure<span class="Sup">b</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">31%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">28%</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Discontinued due to adverse reactions</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">12%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" rowspan="1" valign="top"><p class="First">Discontinued due to other reasons<span class="Sup">c</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="top"><p class="First">11%</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">10%</p></td>
</tr>
</tbody>
</table>
<p>Treatment response by plasma HIV-1 RNA strata is shown in Table 9.</p>
<a name="id_e2eb8e8a-c2d8-4016-91db-4dd0619268cf"></a><table width="456.000">
<caption><span>Table 9. Proportions of Responders through Week 48 by Screening Plasma HIV-1 RNA Levels (CNA3005)</span></caption>
<col width="28.9%">
<col width="21.7%">
<col width="13.2%">
<col width="21.7%">
<col width="14.5%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle">
<span class="Bold">Screening </span><br><span class="Bold">HIV-1 RNA</span><br><span class="Bold">(copies/mL)</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" rowspan="1" valign="middle">
<span class="Bold">Abacavir plus Lamivudine/Zidovudine</span><br><span class="Bold">(n = 262)</span>
</td>
<td class="Botrule" align="center" colspan="2" rowspan="1" valign="middle">
<span class="Bold">Indinavir plus </span><span class="Bold">Lamivudine/Zidovudine <br>(n = 265)</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle"><span class="Bold">&lt;400 copies/mL</span></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle"><span class="Bold">n</span></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle"><span class="Bold">&lt;400 copies/mL</span></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><span class="Bold">n</span></td>
</tr>
<tr>
<td class="Rrule" align="justify" rowspan="1" valign="top">≥10,000 to ≤100,000</td>
<td class="Rrule" align="center" rowspan="1" valign="top">50%</td>
<td class="Rrule" align="center" rowspan="1" valign="top">166</td>
<td class="Rrule" align="center" rowspan="1" valign="top">48%</td>
<td align="center" rowspan="1" valign="top">165</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="justify" rowspan="1" valign="top">&gt;100,000</td>
<td class="Rrule" align="center" rowspan="1" valign="top">48%</td>
<td class="Rrule" align="center" rowspan="1" valign="top">96</td>
<td class="Rrule" align="center" rowspan="1" valign="top">52%</td>
<td class="Botrule" align="center" rowspan="1" valign="top">100</td>
</tr>
</tbody>
</table>
<p>In subjects with baseline viral load greater than 100,000 copies per mL, percentages of subjects with HIV-1 RNA levels less than 50 copies per mL were 31% in the group receiving abacavir versus 45% in the group receiving indinavir.</p>
<p>Through Week 48, an overall mean increase in CD4+ cell count of about 150 cells per mm<span class="Sup">3</span> was observed in both treatment arms. Through Week 48, nine subjects (3.4%) in the group receiving abacavir sulfate (six CDC classification C events and three <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) and three subjects (1.5%) in the group receiving indinavir (two CDC classification C events and one <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) experienced clinical disease progression.</p>
<p>CNA30021 was an international, multicenter, double-blind, controlled trial in which 770 HIV-1-infected, therapy-naive adults were randomized and received either abacavir 600 mg once daily or abacavir 300 mg twice daily, both in combination with lamivudine 300 mg once daily and efavirenz 600 mg once daily. The double-blind treatment duration was at least 48 weeks. Trial participants had a mean age of 37 years; were male (81%), white (54%), black (27%), and American Hispanic (15%). The median baseline CD4+ cell count was 262 cells per mm<span class="Sup">3</span> (range: 21 to 918 cells per mm<span class="Sup">3</span>) and the median baseline plasma HIV-1 RNA was 4.89 log<span class="Sub">10</span> copies per mL (range: 2.60 to 6.99 log10 copies per mL).</p>
<p>The outcomes of randomized treatment are provided in Table 10.</p>
<a name="id_b60d7d27-3c0f-4be2-ae14-c582b4cc36bf"></a><table width="0.000">
<caption><span>Table 10. Outcomes of Randomized Treatment through Week 48 (CNA30021)</span></caption>
<col>
<col>
<col>
<tfoot>
<tr><td align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">a</span> Subjects achieved and maintained confirmed HIV-1 RNA less than 50 copies per mL (less than 400 copies per mL) through Week 48 (Roche AMPLICOR Ultrasensitive HIV-1 MONITOR standard test version 1.0).</p></td></tr>
<tr><td align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">b</span> Includes viral rebound, failure to achieve confirmed less than 50 copies per mL (less than 400 copies per mL) by Week 48, and insufficient viral load response.</p></td></tr>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="3" rowspan="1" valign="top"><p class="First"><span class="Sup">c</span> Includes consent withdrawn, lost to follow up, protocol violations, clinical progression, and other.</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" rowspan="1" valign="middle"><span class="Bold">Outcome</span></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Abacavir 600 mg q.d. plus EPIVIR® plus Efavirenz</span><br><span class="Bold">(n = 384)</span>
</td>
<td class="Botrule" align="center" rowspan="1" valign="middle">
<span class="Bold">Abacavir 300 mg b.i.d. plus EPIVIR plus Efavirenz</span><br><span class="Bold">(n = 386)</span>
</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Responder<span class="Sup">a</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">64% (71%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">65% (72%)</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Virologic failure<span class="Sup">b</span></p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">11% (5%)</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">11% (5%)</p></td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="1" valign="top"><p class="First">Discontinued due to adverse reactions</p></td>
<td class="Rrule" align="center" rowspan="1" valign="top"><p class="First">13%</p></td>
<td align="center" rowspan="1" valign="top"><p class="First">11%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" rowspan="1" valign="top"><p class="First">Discontinued due to other reasons<span class="Sup">c</span></p></td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="top"><p class="First">11%</p></td>
<td class="Botrule" align="center" rowspan="1" valign="top"><p class="First">13%</p></td>
</tr>
</tbody>
</table>
<p>After 48 weeks of therapy, the median CD4+ cell count increases from baseline were 188 cells per mm<span class="Sup">3</span> in the group receiving abacavir 600 mg once daily and 200 cells per mm<span class="Sup">3</span> in the group receiving abacavir 300 mg twice daily. Through Week 48, six subjects (2%) in the group receiving abacavir 600 mg once daily (four CDC classification C events and two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) and ten subjects (3%) in the group receiving abacavir 300 mg twice daily (seven CDC classification C events and three <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) experienced clinical disease progression. None of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were attributed to trial medications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ceedef33-bcda-48f8-be95-8e7113e9ce1a"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Pediatric Trials</h2>
<p class="First"><span class="Bold Italics">Therapy-experienced Pediatric Subjects </span><br>CNA3006 was a randomized, double-blind trial comparing abacavir 8 mg per kg twice daily plus lamivudine 4 mg per kg twice daily plus zidovudine 180 mg per m<span class="Sup">2</span> twice daily versus lamivudine 4 mg per kg twice daily plus zidovudine 180 mg per m<span class="Sup">2</span> twice daily. Two hundred and five therapy-experienced pediatric subjects were enrolled: female (56%), white (17%), black (50%), Hispanic (30%), median age of 5.4 years, baseline CD4+ cell percent greater than 15% (median = 27%), and median baseline plasma HIV-1 RNA of 4.6 log<span class="Sub">10</span> copies per mL. Eighty percent and 55% of subjects had prior therapy with zidovudine and lamivudine, respectively, most often in combination. The median duration of prior nucleoside analogue therapy was 2 years. At 16 weeks the proportion of subjects responding based on plasma HIV-1 RNA less than or equal to 400 copies per mL was significantly higher in subjects receiving abacavir plus lamivudine plus zidovudine compared with subjects receiving lamivudine plus zidovudine, 13% versus 2%, respectively. Median plasma HIV-1 RNA changes from baseline were -0.53 log<span class="Sub">10</span> copies per mL in the group receiving abacavir plus lamivudine plus zidovudine compared with -0.21 log<span class="Sub">10</span> copies per mL in the group receiving lamivudine plus zidovudine. Median CD4+ cell count increases from baseline were 69 cells per mm<span class="Sup">3</span> in the group receiving abacavir plus lamivudine plus zidovudine and 9 cells per mm<span class="Sup">3</span> in the group receiving lamivudine plus zidovudine.</p>
<p><span class="Bold">Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Company’s ZIAGEN<span class="Sup">®</span> (abacavir sulfate) tablets and oral solution. However, due to ViiV Healthcare Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</span></p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="_81c87ad9-dcc1-582e-c9d3-b8bbf32876c0"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES </h1>
<p class="First">1. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. <span class="Italics">Lancet.</span> 2008; 371 (9622):1417-1426.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_b7f5c009-31ad-429f-9731-2e2fcb9f7c3b"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Abacavir Tablets, USP are available containing abacavir sulfate, USP equivalent to 300 mg of abacavir. The 300 mg tablets are yellow, biconvex, scored, modified capsule-shaped, film-coated tablets engraved with “APO? on one side and “AB? bisect “300? on the other side. </p>
<p>They are packaged as follows:</p>
<p>Bottles of 60 tablets (NDC 60505-3583-6).</p>
<p>Unit Dose packs of 60 tablets (NDC 60505-3583-0). Each pack contains 6 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 10 tablets each.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. </span></p>
<p>Dispense in original container with attached prescribing information that contains the Medication Guide and a Warning Card.<span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_fda3e51d-acf5-4fe9-9a61-3738c0841d29"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Medication Guide). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8d98ea62-2b0c-421c-90c7-ac225fe4e687"></a><a name="section-16.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span> </span><br><span class="Bold Italics">Inform patients </span></p>
<ul>
<li>that a Medication Guide and Warning Card summarizing the symptoms of the abacavir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> and other product information will be dispensed by the pharmacist with each new prescription and refill of abacavir tablets, and instruct the patient to read the Medication Guide and Warning Card every time to obtain any new information that may be present about abacavir tablets. The complete text of the Medication Guide is reprinted at the end of this document.</li>
<li>to carry the Warning Card with them<span class="Bold">.</span>
</li>
<li>how to identify a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> <span class="Italics">[see <a href="#i4i_section_id_cd1f73fd-de18-42ac-acb2-80fe5777c696"> Warnings and Precautions (5.1)</a>, <a href="#i4i_section_id_8d98ea62-2b0c-421c-90c7-ac225fe4e687"> Medication Guide</a>].</span>
</li>
<li>that if they develop symptoms consistent with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> they should call their healthcare provider right away to determine if they should stop taking abacavir tablets.</li>
<li>that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> can worsen and lead to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if abacavir tablets are not immediately discontinued.</li>
<li>that in one trial, more severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> were seen when abacavir was dosed 600 mg once daily.</li>
<li>to not restart abacavir tablets or any other abacavir-containing product following a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> because more severe symptoms can occur within hours and may include life-threatening <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>that a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> is usually reversible if it is detected promptly and abacavir tablets are stopped right away. </li>
<li>that if they have interrupted abacavir tablets for reasons other than symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (for example, those who have an interruption in drug supply), a serious or fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> may occur with reintroduction of abacavir. </li>
<li>to not restart abacavir tablets or any other abacavir-containing product without medical consultation and that restarting abacavir needs to be undertaken only if medical care can be readily accessed by the patient or others. </li>
<li>Abacavir tablets should not be coadministered with EPZICOM<span class="Sup"></span> (abacavir sulfate and lamivudine) tablets, TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets, or TRIZIVIR<span class="Sup"></span>(abacavir sulfate, lamivudine, and zidovudine) tablets.</li>
</ul>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> </span><br>Inform patients that some HIV medicines, including abacavir tablets, can cause a rare, but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) <span class="Italics">[see <a href="#id_9c52baa5-0e88-4758-855f-4cfdfb325aa0"> Boxed Warning</a>, <a href="#i4i_section_id_c829b3a3-8657-4da8-aebe-5df2726c86e9"> Warnings and Precautions (5.2)</a>]</span>.</p>
<p><span class="Bold Italics">Redistribution/Accumulation of Body Fat <br></span>Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time <span class="Italics">[see <a href="#i4i_section_id_917c3387-e958-44f6-ad3c-60cf15a55fb1"> Warnings and Precautions (5.4)</a>].</span></p>
<p><span class="Bold">Information about HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> </span><br>Inform patients that abacavir is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients must remain on continuous HIV therapy to control HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and decrease HIV-related illness. Patients should be told that sustained decreases in plasma HIV-1 RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients should remain under the care of a physician when using abacavir tablets. </p>
<p>Patients should be informed to take all HIV medications exactly as prescribed. If you miss a dose of abacavir, take it as soon as you remember. Do not take 2 doses at the same time. If you are not sure about your dosing, call your healthcare provider.</p>
<p>Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others. </p>
<p>• <span class="Bold">Do not <span class="Bold">re-use or</span> share needles or other injection equipment. </span></p>
<p>• <span class="Bold"></span><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades. </span></p>
<p>• <span class="Bold"></span> Continue to practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</p>
<p><span class="Bold">•</span> Female patients should be advised not to<span class="None"> </span>breastfeed<span class="None">. </span>Mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk. </p>
<p></p>
<p>All registered trademarks in this document are the property of their respective owners.</p>
<p></p>
<p><span class="Bold">APOTEX INC.</span> <br><span class="Bold">ABACAVIR TABLETS, USP 300 mg</span></p>
<table><tbody class="Headless">
<tr class="First">
<td><span class="Bold">Manufactured by</span></td>
<td><span class="Bold">Manufactured for</span></td>
</tr>
<tr>
<td>Apotex Research Pvt. Ltd.</td>
<td>Apotex Corp.</td>
</tr>
<tr>
<td>Bangalore - 560 099</td>
<td>Weston, Florida</td>
</tr>
<tr class="Last">
<td>India</td>
<td>33326</td>
</tr>
</tbody></table>
<p><span class="Bold"></span><span class="Bold"></span><span class="Bold"></span>Revised: September 2015</p>
<p>Rev 6</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="_b237eb9d-2bf7-f089-2b60-726bd471afe7"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">MEDICATION GUIDE </span></p>
<p><span class="Bold"></span><span class="Bold">Abacavir Tablets, USP</span></p>
<p>(A bak' a vir)<span class="Bold"></span><span class="Bold"></span></p>
<p>Read this Medication Guide before you start taking abacavir tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Be sure to carry your abacavir tablets Warning Card with you at all times.</p>
<p><span class="Bold Underline"></span><span class="Bold">What is the most important information I should know about abacavir tablets?</span></p>
<p><span class="Bold">1. </span><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>).</span></p>
<p><span class="Bold"></span>Abacavir tablets contains abacavir (also contained in EPZICOM<span class="Sup">®</span>, TRIUMEQ<span class="Sup">®</span> and TRIZIVIR<span class="Sup">®</span>). Patients taking abacavir tablets may have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>) that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your risk of this <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> is much higher if you have a gene variation called HLA-B*5701. <span class="Bold"></span>Your healthcare provider can determine with a blood test if you have this gene variation.</p>
<p><span class="Bold">If you get a symptom from two or more of the following groups while taking abacavir tablets, call your healthcare provider right away to find out if you should stop taking abacavir tablets. </span></p>
<table><tbody class="Headless">
<tr class="First">
<th></th>
<th align="left"><span class="Bold">Symptom(s)</span></th>
</tr>
<tr>
<td><span class="Bold">Group 1</span></td>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> </span></td>
</tr>
<tr>
<td><span class="Bold">Group 2</span></td>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></td>
</tr>
<tr>
<td><span class="Bold">Group 3</span></td>
<td><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, abdominal ( stomach area) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></span></td>
</tr>
<tr>
<td><span class="Bold">Group 4</span></td>
<td><span class="Bold">Generally ill feeling, extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, or achiness</span></td>
</tr>
<tr class="Last">
<td colspan="1"><span class="Bold">Group 5</span></td>
<td colspan="1"><span class="Bold"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> </span></td>
</tr>
</tbody></table>
<p><span class="Bold"></span> A list of these symptoms is on the Warning Card your pharmacist gives you. <span class="Bold">Carry this Warning Card with you at all times.</span></p>
<p><span class="Bold"></span><span class="Bold">If you stop abacavir tablets because of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, never take abacavir tablets or any other abacavir-containing medicine (EPZICOM<span class="Bold">, TRIUMEQ</span> and TRIZIVIR) again.</span> If you take abacavir tablets or any other abacavir-containing medicine again after you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span><span class="Bold">, <span class="Bold">within hours </span></span>you may get <span class="Bold"></span><span class="Bold"><span class="Bold">life-threatening symptoms </span></span><span class="Bold"></span>that may include <span class="Bold"><span class="Bold">very <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> </span></span>or<span class="Bold"><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span></span>If you stop abacavir tablets for any other reason, even for a few days, and you are not allergic to abacavir, talk with your healthcare provider before taking it again. Taking abacavir tablets again can cause a serious allergic or life-threatening reaction, even if you never had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to it before.</p>
<p><span class="Bold">If your healthcare provider tells you that you can take abacavir again, start taking it when you are around medical help or people who can call a healthcare provider if you need one.</span></p>
<p><span class="Bold">2. <span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> (buildup of acid in the blood). Some human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) medicines, including abacavir tablets, can cause a rare but serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. <span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is <span class="Bold">a serious medical emergency that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and must be treated in <span class="Bold">the hospital. </span></span></span></span></span></p>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following signs or symptoms of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>:</span></p>
<ul>
<li>
<span class="Bold"></span>you feel very weak or tired</li>
<li>you have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></li>
<li>you have trouble breathing</li>
<li>you have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>you feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs</li>
<li>you feel dizzy or light-headed</li>
<li>you have a fast or irregular heartbeat<span class="Bold"><span class="Bold"><span class="Bold"><span class="Bold"><span class="Bold"></span></span></span></span></span>
</li>
</ul>
<p><span class="Bold">3. </span><span class="Bold">Serious liver problems. Some people who have taken medicines like abacavir tablets have developed serious liver problems called hepatotoxicity, <span class="Bold">with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and fat in the liver (steatosis).</span></span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with steatosis is a serious medical emergency that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following signs or symptoms of liver problems:</span></p>
<ul>
<li>your skin or the white part of your eyes turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>)</li>
<li>your urine turns dark</li>
<li>your bowel movements (stools) turn light in color</li>
<li>you don’t feel like eating food for several days or longer</li>
<li>you feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>)</li>
<li>you have lower stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">You may be more likely to get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or serious liver problems if you are female, <span class="Bold">very overweight, or have been taking nucleoside analogue medicines for a long time.</span></span></p>
<p><span class="Bold">What are abacavir tablets? </span></p>
<p>Abacavir tablets are a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. Abacavir is a medicine called a nucleoside analogue reverse transcriptase inhibitor (NRTI). Abacavir is always used with other anti-HIV medicines. When used in combination with these other medicines, abacavir helps lower the amount of HIV in your blood. </p>
<ul>
<li>
<span class="Bold">Abacavir tablets </span><span class="Bold">does not cure <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> or AIDS. </span>
</li>
<li>It is not known if abacavir will help you live longer or have fewer of the medical problems that people get with HIV or AIDS. </li>
<li>It is very important that you see your doctor regularly while you are taking abacavir tablets. <span class="Bold"></span>
</li>
</ul>
<p><span class="Bold">Who should not take abacavir tablets? </span></p>
<p><span class="Bold">Do not take abacavir tablets if you:</span></p>
<ul>
<li><span class="Bold">are allergic to abacavir or any of the ingredients in abacavir tablets. <span class="Bold">See the end of this Medication Guide for a complete list of ingredients in abacavir tablets.</span></span></li>
<li>
<span class="Bold">have certain liver problems.</span><span class="Bold"><span class="Bold"></span></span>
</li>
</ul>
<p><span class="Bold Underline"></span><span class="Bold Underline"></span><span class="Bold">What should I tell my healthcare provider before taking abacavir tablets? </span></p>
<p><span class="Bold">Before you take abacavir tablets, tell your healthcare provider if you:</span></p>
<ul>
<li>
<span class="Bold">have been tested and know whether or not you have a particular gene variation called HLA-B*5701</span>. </li>
<li>
<span class="Bold">have <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or have other liver problems</span>. </li>
<li><span class="Bold">have heart problems, smoke, or have diseases that increase your risk of heart disease such as high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</span></li>
<li>
<span class="Bold">are pregnant or plan to become pregnant. </span>Taking abacavir during pregnancy has not been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Talk to your healthcare provider if you are pregnant or plan to become pregnant.</li>
<li>
<span class="Bold">Pregnancy Registry</span>. If you take abacavir tablets while you are pregnant, talk to your healthcare provider about how you can take part in the Pregnancy Registry for abacavir tablets. The purpose of the pregnancy registry is to collect information about the health of you and your baby.</li>
<li> are breastfeeding or plan to breastfeed.<span class="Bold"><span class="Bold"> Do not breastfeed if you take abacavir</span>. </span>
</li>
<li> You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby.</li>
<li>
<span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and nonprescription medicines, vitamins, and herbal supplements.</li>
</ul>
<p><span class="Bold">Especially tell your healthcare provider if you take: </span></p>
<ul>
<li>alcohol</li>
<li>methadone</li>
<li>TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine)</li>
<li>EPZICOM (abacavir sulfate and lamivudine)</li>
<li>TRIUMEQ (abacavir, dolutegravir, and lamivudine)</li>
</ul>
<p>Ask your healthcare provider if you are not sure if you take one of the medicines listed above.</p>
<p>Abacavir tablets may affect the way other medicines work, and other medicines may affect how abacavir tablets works.</p>
<p>Know the medicines you take. Keep a list of your medicines with you to show to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take abacavir tablets? </span></p>
<ul>
<li><span class="Bold">Take abacavir tablets exactly as your healthcare provider tells you to take it.</span></li>
<li>
<span class="Bold">Abacavir is taken by mouth as a tablet or liquid.</span><span class="Bold"></span>
</li>
<li>
<span class="Bold">Abacavir</span> tablets may be taken with or without food.</li>
<li>Do not skip doses. If you miss a dose of abacavir, take it as soon as you remember. Do not take 2 doses at the same time. If you are not sure about your dosing, call your healthcare provider.</li>
<li>Children aged 3 months and older can also take abacavir. The child’s healthcare provider will decide the right dose and whether the child should take the tablet or liquid, based on the child’s weight. The dose should not be more than the recommended adult dose.</li>
<li>
<span class="Bold">Do not let your abacavir tablets run out.</span> If you stop your anti-HIV medicines, even for a short time, the amount of virus in your blood may increase and the virus may become harder to treat. If you take too much abacavir, call your healthcare provider or poison control center or go to the nearest hospital emergency room right away.<span class="Bold"></span><span class="Bold"></span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of abacavir tablets? </span></p>
<ul>
<li><span class="Bold">Abacavir tablets can cause serious side effects including <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, and liver problems. See “What is the most important information I should know about abacavir tablets?? </span></li>
<li>
<span class="Bold">Changes in immune system (<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>).</span> Your immune system may get stronger and begin to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been hidden in your body for a long time. Tell your healthcare provider if you start having new or worse symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> after you start taking abacavir tablets.</li>
<li>
<span class="Bold">Changes in body fat (fat redistribution).</span> Changes in body fat (<span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> or <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>) can happen in some people taking antiretroviral medicines including abacavir tablets.<p class="First"></p>
</li>
</ul>
<p>These changes may include:</p>
<ul>
<li>more fat in or around your trunk, upper back and neck (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), breast, or chest</li>
<li>loss of fat in your legs, arms, or face</li>
</ul>
<ul><li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>). </span>Some HIV medicines including abacavir tablets may increase your risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</p></li></ul>
<p><span class="Bold">The most common side effects of abacavir in adults include: </span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">bad dreams</span> or <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problems</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p><span class="Bold">The most common side effects of abacavir in children include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>ear, nose, or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">throat infections</span></li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of abacavir tablets. For more information, ask your healthcare provider or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store abacavir tablets? </span></p>
<ul>
<li>Store abacavir tablets at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</li>
<li>Do not freeze abacavir tablets.</li>
<li><span class="Bold">Keep abacavir tablets and all medicines out of the reach of children. </span></li>
</ul>
<p><span class="Bold Underline"></span><span class="Bold">General information for safe and effective use of abacavir tablets </span></p>
<p><span class="Bold Underline"></span> Avoid doing things that can spread <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> to others.</p>
<ul>
<li><span class="Bold">Do not re-use or share needles or other injection equipment. </span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades. </span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with any body fluids such as semen, vaginal secretions, or blood.</li>
</ul>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use abacavir for a condition for which it was not prescribed. Do not give abacavir tablets to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about abacavir tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for the information that is written for healthcare professionals. </p>
<p>For more information call Apotex Corp. at 1-800-706-5575.</p>
<p><span class="Bold"></span></p>
<p><span class="Bold">What are the ingredients in abacavir tablets? </span></p>
<p>Active ingredient: abacavir sulfate, USP</p>
<p>Inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and croscarmellose sodium. The film-coating is made of hypromellose, polyethylene glycol, yellow iron oxide, and titanium dioxide. </p>
<p><span class="None">This Medication Guide has been approved by the US Food and Drug Administration. </span></p>
<p><span class="Bold"></span><span class="Bold Underline"></span> All registered trademarks in this document are the property of their respective owners.<span class="Italics"></span></p>
<p><span class="Bold">APOTEX INC.</span><br><span class="Bold">ABACAVIR TABLETS, USP 300 mg</span></p>
<table><tbody class="Headless">
<tr class="First">
<td><span class="Bold">Manufactured by</span></td>
<td><span class="Bold">Manufactured for</span></td>
</tr>
<tr>
<td>Apotex Research Pvt. Ltd.</td>
<td>Apotex Corp.</td>
</tr>
<tr>
<td>Bangalore-560 099</td>
<td>Weston, Florida</td>
</tr>
<tr class="Last">
<td>India.</td>
<td>33326</td>
</tr>
</tbody></table>
<p>Revised: September 2015</p>
<p>Rev 6</p>
<p><span class="Bold Underline"></span></p>
<p><span class="Bold"></span><span class="Bold"></span><span class="Bold Underline"></span></p>
<p><span class="Bold Underline"></span><span class="Bold"><span class="Bold"></span></span><span class="Bold"></span></p>
<p><span class="Bold"></span></p>
<p></p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_46d67d24-4188-f6f1-5a02-eeab8b5fa1cd"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL — 300 mg BOTTLE LABEL</span></p>
<p>Representative sample of bottle face panel (see <span class="Bold"><a href="#i4i_how_supplied_id_b7f5c009-31ad-429f-9731-2e2fcb9f7c3b">HOW SUPPLIED</a></span> section for complete listing): </p>
<p>60 Tablets NDC 60505-3583-6 </p>
<p>Abacavir Tablets, USP</p>
<p>300 mg</p>
<p>Notice to Authorized Dispenser: Each time Abacavir Tablets are dispensed, give the patient a Medication Guide and Warning Card from carton.</p>
<p>Rx Only APOTEX CORP.</p>
<p></p>
<p><img alt="300mg-btl-label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73ce0bc5-43e2-c57f-0a6a-bdaf9fbaa3c2&amp;name=300mg-btl-label.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_65e974cc-4187-774d-c491-c3a1a2acf87a"></a><a name="section-19"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL — 300 mg BOTTLES CARTON LABEL</span></p>
<p>Representative sample of bottle carton (see <span class="Bold"><a href="#i4i_how_supplied_id_b7f5c009-31ad-429f-9731-2e2fcb9f7c3b">HOW SUPPLIED</a></span> section for complete listing): </p>
<p>NDC 60505-3583-6</p>
<p>60 Tablets </p>
<p>Abacavir Tablets, USP</p>
<p>300 mg</p>
<p>Notice to Authorized Dispenser: Each time Abacavir Tablets are dispensed, give the patient a Medication Guide and Warning Card from carton.</p>
<p>Rx Only APOTEX CORP.</p>
<p></p>
<p><img alt="300mg-btl-carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73ce0bc5-43e2-c57f-0a6a-bdaf9fbaa3c2&amp;name=300mg-btl-carton.jpg"></p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_d95d7c64-d90d-68a1-b0a9-8944099f77fc"></a><a name="section-20"></a><p></p>
<h1>PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL — 300 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTERS</span> CARTON LABEL</span></p>
<p>Representative sample of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> carton face panel (see <span class="Bold"><a href="#i4i_how_supplied_id_b7f5c009-31ad-429f-9731-2e2fcb9f7c3b">HOW SUPPLIED</a></span> section for complete listing): </p>
<p>60 (6 X 10) Unit-Dose Tablets NDC 60505-3583-0</p>
<p>Abacavir Tablets, USP</p>
<p>300 mg</p>
<p>Notice to Authorized Dispenser: Each time Abacavir Tablets are dispensed, give the patient a Medication Guide and Warning Card from carton.</p>
<p>Rx Only APOTEX CORP.</p>
<p><img alt="<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=73ce0bc5-43e2-c57f-0a6a-bdaf9fbaa3c2&amp;name=Untitled.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABACAVIR SULFATE 		
					</strong><br><span class="contentTableReg">abacavir sulfate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-3583</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ABACAVIR SULFATE</strong> (ABACAVIR) </td>
<td class="formItem">ABACAVIR</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (modified capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;AB;300</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-3583-6</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60505-3583-0</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201570</td>
<td class="formItem">12/17/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Apotex Corp
							(845263701)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Apotex Inc (209429182)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Apotex Research Private Limited</td>
<td class="formItem"></td>
<td class="formItem">862584104</td>
<td class="formItem">manufacture(60505-3583), analysis(60505-3583)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a1f22bbf-6949-f67c-48ed-74d3d7f6c900</div>
<div>Set id: 73ce0bc5-43e2-c57f-0a6a-bdaf9fbaa3c2</div>
<div>Version: 6</div>
<div>Effective Time: 20150901</div>
</div>
</div> <div class="DistributorName">Apotex Corp</div></p>
</body></html>
